^
    Back
    Association details:
    Biomarker:BRAF mutation
    Cancer:Melanoma
    Drug:ARN22089 (CDC42 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    Abstract 5324: Structure-based design of CDC42/RHOJ effector inhibitors for the treatment of cancer

    Published date:
    05/15/2020
    Excerpt:
    Short term treatment of nascent melanoma tumors with ARN22089 halted the growth of BRAF mutant autochthonous mouse melanoma tumors, slowed the growth of melanoma patient-derived xenografts, and induced tumor necrosis in PDX models.
    DOI:
    10.1158/1538-7445.AM2020-5324